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Markov Modeling of Breast Cancer
Chunling Cong

Chris P. Tsokos

University of South Florida

Previous work with respect to the treatments and relapse time for breast cancer patients is extended by
applying a Markov chain to model three different types of breast cancer patients: alive without ever
having relapse, alive with relapse, and deceased. It is shown that combined treatment of tamoxifen and
radiation is more effective than single treatment of tamoxifen in preventing the recurrence of breast
cancer. However, if the patient has already relapsed from breast cancer, single treatment of tamoxifen
would be more appropriate with respect to survival time after relapse. Transition probabilities between
three stages during different time periods, 2-year, 4-year, 5-year, and 10-year, are also calculated to
provide information on how likely one stage moves to another stage within a specific time period.
Key words: Markov chain, breast cancer, relapse time, tamoxifen and radiation.
patients in three different stages who were given
different treatments. One group of patients
received combined treatments of tamoxifen and
radiation, and the other group received only
tamoxifen. Figure 1 shows the three stages of
interest in the study are: alive with no relapse,
alive with relapse, and deceased. Even though
breast cancer patients who have recurrence may
be treated and recover from breast cancer to
become active with no relapse, due to the fact
that the data does not include any observations
of that process, we consider the second statealive with relapse as those patients who once
had relapse and are still alive, regardless of
whether they have recovered from breast cancer
or not.

Introduction
The Markov (1906) chain model has been
applied in various fields such as physics,
queuing theory, internet application, economics,
finance, and social sciences among others. As an
effective and efficient way of describing a
process in which an individual moves through a
series of states (stages) in continuous time,
homogeneous Markov models have also been
extensively used in health sciences where the
progression of certain diseases are of great
importance to both doctors and patients. In the
present study, the main objective is to
investigate the progression of breast cancer in

Figure 1: Three Stages of Breast Cancer
Modeling
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Methodology
Between December 1992 and June 2000, a total
of 769 women were enrolled and randomized in
the study. Among these, 386 received combined
radiation and tamoxifen (RT+Tam), and the
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between the stages at different times satisfy the
Markov property: the conditional probability of
future one-step-event conditioned on the entire
past of the process is just conditioned on the
present stage of the process. In other words, the
one-step future stage depends only on the
present stage:

remaining 383 received tamoxifen (Tam) only.
The last follow-up was conducted in the summer
of 2002. As shown in Figure 2, only those 641
patients enrolled at the Princess Margaret
Hospital are included: 320 and 321 in RT+Tam
and Tam treatment groups, respectively.
Figure 2: Breast Cancer Data

P( X t +1 = xt +1 | X t = xt , X t −1 = xt −1,..., X1 = x1) (1)
= P( X t +1 = xt +1 | X t = xt )

641Total

320
RT+Tam

for every sequence x1 ,..., xt , xt +1 of elements of

321
Tam

S and every t ≥ 1 .

The transition probability from stage i to
stage j at time t and transition intensity are
defined by
(2)
pij (t ) = p ( X t +1 = j | X t = i ) ,

This data was used by Fyles, et al. and
was later analyzed by Ibrahim, et al. Analysis
was conducted on this data with respect to the
treatment effect of the two different treatments
using decision tree and modeled relapse time
using AFT and Cox-PH model. Mixture models
were also applied to compare the cure rate of the
two groups.

and

qij (t ) = lim
h →0

P( X (t + h) = j | X (t ) = i )
, (3)
h

where h is the time interval.
If the transition probabilities do not
depend on time, pij (t ) can simply be written as

The Markov Chain Model
The Markov chain is a model for a finite
or
infinite
random
process
sequence
X = { X 1 , X 2,..., X N }. Unlike the independent

pij , then the Markov chain is called timehomogeneous. If not specified, the following
analysis is based on time-homogeneous Markov
chain. A transition probability matrix P (t )
consisting of all the transition probabilities
between stages in a matrix form is given by:

identical distribution (i.i.d) model that assumes
the independency of a sequence of events X i ’s,
the Markov model takes into account the
dependencies among the X i ’s.
Consider
a
random
process
X = { X t }t ≥1 = { X 1, X 2 ,...} of random variables

 p11 (t )
 p (t )

P (t ) =  21
 ...
 ps1 (t )

taking values in a discrete set space of stages
S = {1, 2, 3,..., s} where X t represents the state
of the process of an individual at time t. The
transitions possible among the three stages in
this study, alive without relapse, alive with
relapse, and deceased are shown in Figure 1
indicated by arrows. Consider a realization of
the history of the process up to and including
time t, as { X t = xt , X t −1 = xt −1 ,..., X 1 = x1},

p12 (t ) ...
p22 (t ) ...
...

...

ps 2 (t ) ...

p1s (t ) 
p2 s (t ) 
 , (4)
... 
pss (t ) 

where probabilities in each row add up to 1.
Thus, it is 100% certain that for any individual
at time t is in one of the stages and the sum of
probabilities of being in each stage is 1.
The transition probability matrix can be
calculated by taking the matrix exponential of
the scaled transition intensity matrix defined by

where xt , xt −1 ,..., x1 is a sequence of stages at
different times. A random process is called a
Markov Chain if the conditional probabilities

P (t ) = Exp (tQ ) ,
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Scenario 3
If the time of death is known or
j = death , but the stage on the previous instant
before death is unknown as denoted by k ( k
could be any possible stage between stage i and
death), the contribution to the likelihood
function from this pair of stages is:

where

 q11 q12
q
q

Q =  21 22
 ... ...
 qs1 qs 2

... q1s 
... q2 s 
,
... ... 
... qss 

(6)

Lij =  pik (t j − ti )qkj .

and q ij denotes the transition intensity from
stage i to stage j .
The exponential of a matrix
defined by

A is

Exp( A) = 1 + A2 / 2!+ A3 / 3!+ ... ,

Results
The breast cancer patients were divided into two
groups RT+Tam and Tam based on the different
treatments they received. For those patients who
received combined treatments, 26 patients
experienced relapse, 13 patients died without
recurrence of breast cancer during the entire
period of the study, and 14 died after recurrence
of breast cancer. For the patients in the Tam
group, 51 patients experienced relapse, 10 died
without reoccurrence of breast cancer, and 13
died after recurrence of breast cancer.
As can be observed from the transition
intensity matrixes for both groups RT+Tam and
Tam as shown in Tables 1 and 2, patients who
received single treatment have a higher
transition intensity form Stage 1 to Stage 2, thus,
they are more likely to have breast cancer
recurrence. Thus, the probability of that
happening in the Tam group is higher than that
of the RT+Tam group. For those patients who
died without relapse, there is no significant
difference between the two treatments as
illustrated by the intensity form Stage 1 to Stage
3.
Combined treatment is also more
effective than a single treatment with respect to
the possibility of death without relapse as can be
observed from the transition intensity from
Stage 1 to Stage 3. However, for those who
already experienced relapse of breast cancer,
patients who received combined treatments are
more likely to die than those who received a
single treatment. Therefore, combined treatment
should be chosen over single treatment to avoid
recurrence, but for those patients who already
had breast cancer relapse, it would be advisable
to choose a single treatment to extend the time
from recurrence to death.

(7)

where each summand in the series is the matrix
products. In this manner, once the intensity
matrix is given, the transition probabilities can
be calculated as shown above.
Next, the intensity matrix and transition
probabilities matrix can be obtained by
maximizing the likelihood L (Q ) which is a
function of Q . Consider an individual consisting
of

a

series

(t1 , t2 ,..., tn ) and
stages ( x1 , x2 ,..., xn ).
More

of

(10)

k≠ j

times

corresponding
specifically, consider a pair of successive stages
observed to be i and j at time ti and t j . Three
scenarios are proposed and considered here.

Scenario 1
If the information for the individual is
obtained at arbitrary observation times (the exact
time of the transition of stages is unknown) the
contribution to the likelihood from this pair of
states is:
(8)
Lij = pij (t j − ti ) .
Scenario 2
If the exact times of transitions between
different stages are recorded and there is no
transition between the observation times, the
contribution to the likelihood from this pair of
stages is:
(9)
Lij = pij (t j − ti ) qij .

628

CONG & TSOKOS
transition probabilities could help provide a
clearer view of how one stage transits to another
stage within a given time period.

Figures 3 and 4 illustrate the
effectiveness of the two treatments with respect
to the survival probabilities and also show the
survival curves of the patients who had
recurrence and who had no recurrence in each
treatment group.
From the above analysis, the proposed
Markov chain model provides recommendations
for which treatment to choose for breast cancer
patients with respect to relapse and survival
time. Moreover, it provides patients with very
important information on the exact time or
possibilities of recurrence and death. Estimated
mean sojourn times in each transient stage for
patients who received combined treatment are
43.46 and 3.25 in Stage 1 and Stage 2,
respectively. Estimated mean sojourn times for
patients who received single treatment are 25.53
and 11.72 in Stage 1 and Stage 2. This further
confirms that patients with combined treatment
will remain in Stage 1 longer than those with
single treatment; however, for patients who had
relapse of breast cancer, patients with single
treatment will stay alive longer than those with
combined treatment.
Another goal of this study was to
provide a transition probability matrix at
different times so that given a specific time
period, the probability that a patient in a given
stage will transit to another stage could be
conveyed. Tables 5a-8b give 2-year, 4-year, 5year and 10-year transition probability matrixes
of patients in RT+Tam and Tam.
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Table 1: Transition Intensity Matrix of RT+Tam
Stage 1
Stage 2
-0.02301
0.01957

Stage 1

Stage 3
0.0034

Stage 2

0

-0.3074

0.3074

Stage 3

0

0

0

Table 2: Transition Intensity Matrix of Tam
Stage 1
Stage 2
-0.03917
0.03528

Stage 1

Stage 3
0.003889

Stage 2

0

-0.08533

0.08533

Stage 3

0

0

0

1.0

Figure 3: Survival Curves of Patients in RT+Tam
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1.0

Figure 4: Survival Curves of Patients in Tam
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Table 5a: 2-year transition matrix for RT+Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.9550
0.0285
0.0165
Stage 2
0
0.5408
0.4592
Stage 3
0
0
0

Table 5b: 2-year transition matrix for Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.9247
0.0623
0.0130
Stage 2
0
0.8431
0.1569
Stage 3
0
0
0

Table 6a: 4-year transition matrix for RT+Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.9121
0.0426
0.0453
Stage 2
0
0.2925
0.7075
Stage 3
0
0
0

Table 6b: 4-year transition matrix for Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.8550
0.1102
0.0348
Stage 2
0
0.7108
0.2892
Stage 3
0
0
0

Table 7a: 5-year transition matrix for RT+Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.8913
0.0466
0.0621
Stage 2
0
0.2151
0.7849
Stage 3
0
0
0

Table 7b: 5-year transition matrix for Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.8221
0.1295
0.0484
Stage 2
0
0.6527
0.3473
Stage 3
0
0
0

Table 8a: 10-year transition matrix for RT+Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.7945
0.0515
0.1540
Stage 2
0
0.0463
0.9537
Stage 3
0
0
0

Table 8b: 10-year transition matrix for Tam
Stage 1
Stage 2
Stage 3
Stage 1
0.6759
0.1910
0.1331
Stage 2
0
0.4260
0.5740
Stage 3
0
0
0
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